Aura Biosciences (AURA) Competitors $6.67 +0.04 (+0.60%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA vs. AMPH, CALT, GPCR, AUPH, WVE, NAGE, MLYS, RCUS, SYRE, and AKBAShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include Amphastar Pharmaceuticals (AMPH), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Aurinia Pharmaceuticals (AUPH), Wave Life Sciences (WVE), Niagen Bioscience (NAGE), Mineralys Therapeutics (MLYS), Arcus Biosciences (RCUS), Spyre Therapeutics (SYRE), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Its Competitors Amphastar Pharmaceuticals Calliditas Therapeutics AB (publ) Structure Therapeutics Aurinia Pharmaceuticals Wave Life Sciences Niagen Bioscience Mineralys Therapeutics Arcus Biosciences Spyre Therapeutics Akebia Therapeutics Amphastar Pharmaceuticals (NASDAQ:AMPH) and Aura Biosciences (NASDAQ:AURA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation. Does the media refer more to AMPH or AURA? In the previous week, Amphastar Pharmaceuticals had 4 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for Amphastar Pharmaceuticals and 1 mentions for Aura Biosciences. Aura Biosciences' average media sentiment score of 1.87 beat Amphastar Pharmaceuticals' score of 0.99 indicating that Aura Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Amphastar Pharmaceuticals Positive Aura Biosciences Very Positive Do insiders and institutionals hold more shares of AMPH or AURA? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Aura Biosciences shares are owned by institutional investors. 27.5% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 5.4% of Aura Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Is AMPH or AURA more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Aura Biosciences' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Aura Biosciences N/A -41.57%-36.43% Which has more risk and volatility, AMPH or AURA? Amphastar Pharmaceuticals has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Aura Biosciences has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Which has preferable valuation and earnings, AMPH or AURA? Amphastar Pharmaceuticals has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$730.66M1.71$137.54M$2.769.58Aura BiosciencesN/AN/A-$76.41M-$1.90-3.51 Does the MarketBeat Community favor AMPH or AURA? Amphastar Pharmaceuticals received 365 more outperform votes than Aura Biosciences when rated by MarketBeat users. Likewise, 65.83% of users gave Amphastar Pharmaceuticals an outperform vote while only 63.64% of users gave Aura Biosciences an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39365.83% Underperform Votes20434.17% Aura BiosciencesOutperform Votes2863.64% Underperform Votes1636.36% Do analysts rate AMPH or AURA? Amphastar Pharmaceuticals currently has a consensus target price of $32.33, indicating a potential upside of 22.29%. Aura Biosciences has a consensus target price of $22.00, indicating a potential upside of 229.84%. Given Aura Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Aura Biosciences is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryAmphastar Pharmaceuticals beats Aura Biosciences on 12 of the 18 factors compared between the two stocks. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$335.29M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-3.8632.9027.1719.96Price / SalesN/A466.20410.96157.63Price / CashN/A168.6838.2534.64Price / Book1.463.427.064.69Net Income-$76.41M-$72.35M$3.23B$248.14M7 Day Performance2.62%3.01%0.77%0.95%1 Month Performance26.81%20.80%9.67%5.74%1 Year Performance-7.36%-17.10%32.02%14.73% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences2.7044 of 5 stars$6.67+0.6%$22.00+229.8%-7.9%$335.29MN/A-3.8650Positive NewsAMPHAmphastar Pharmaceuticals3.7808 of 5 stars$26.62+2.4%$32.33+21.5%-34.6%$1.25B$730.66M8.871,620CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.485 of 5 stars$20.51-2.9%$76.50+273.0%-57.3%$1.18BN/A-27.72136Positive NewsAnalyst RevisionGap UpAUPHAurinia Pharmaceuticals3.3379 of 5 stars$8.14-0.6%$11.50+41.3%+51.0%$1.10B$247.30M-54.26300Positive NewsAnalyst RevisionWVEWave Life Sciences4.4492 of 5 stars$7.05-2.4%$21.17+200.2%+12.7%$1.09B$104.94M-6.35240Positive NewsAnalyst ForecastAnalyst RevisionNAGENiagen Bioscience1.4817 of 5 stars$13.43+3.7%$18.00+34.0%N/A$1.06B$107.93M79.00120Analyst ForecastMLYSMineralys Therapeutics3.0567 of 5 stars$16.19+0.4%$38.00+134.7%+18.4%$1.06BN/A-4.4528Positive NewsAnalyst ForecastRCUSArcus Biosciences2.568 of 5 stars$9.86-1.1%$24.13+144.7%-40.6%$1.04B$141M-3.13500Options VolumeAnalyst RevisionSYRESpyre Therapeutics2.4041 of 5 stars$17.16+1.1%$53.40+211.2%-52.1%$1.03B$890K-2.3073Positive NewsAKBAAkebia Therapeutics3.9758 of 5 stars$3.83-3.5%$6.75+76.2%+214.7%$1.01B$184.91M-16.65430High Trading Volume Related Companies and Tools Related Companies Amphastar Pharmaceuticals Competitors Calliditas Therapeutics AB (publ) Competitors Structure Therapeutics Competitors Aurinia Pharmaceuticals Competitors Wave Life Sciences Competitors Niagen Bioscience Competitors Mineralys Therapeutics Competitors Arcus Biosciences Competitors Spyre Therapeutics Competitors Akebia Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AURA) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AURA Stock Free AURA Stock Alerts